Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

145.99 +0.79 (+0.54%)
Streaming Delayed Price Updated: 2:36 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
California Judge Rules For Drugmakers In Major Opioid Litigation
A California judge cleared four drugmakers of liability, accusing the companies of causing widespread opioid addiction in the state. Teva Pharmaceuticals Industries Ltd... 
Via Benzinga
Crypto Punk Sets The NFT World On Fire
“Crypto Punk”, a Non-Fungible Token (NFT), sold for a stunning $532 million, setting yet another high water mark for this odd asset class. 
Via Talk Markets
AbbVie (ABBV) Q3 2021 Earnings Call Transcript
ABBV earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why AbbVie Shares Are Rising Today
AbbVie Inc (NYSE: ABBV) is trading higher Friday after the company announced better-than-expected third-quarter financial results and raised guidance above estimates. AbbVie... 
Via Benzinga
AbbVie's Major Depressive Disorder Candidate Shows Mixed Result In Late-Stage Trials
AbbVie Inc (NYSE: ABBV) has announced topline results from two Phase 3 trials, Study 3111-301-001 and Study 3111-302-001, of cariprazine (Vraylar) as an adjunctive... 
Via Benzinga
AbbVie Stock Nears Breakout After Topping Forecasts As Botox Sales Rocket
AbbVie stock inched higher Friday after the company beat third-quarter forecasts. 
Via Investor's Business Daily
Gargantuan Earnings Week Ahead
Via Talk Markets
AbbVie Stock Gains After Hiking FY21 Earnings Outlook, Annual Dividend
AbbVie Inc (NYSE: ABBV) reports Q3 adjusted EPS of $3.33, higher than $2.83 reported a year ago and beating the consensus of $3.22. Overall sales increased 11.2% Y/Y to... 
Via Benzinga
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
FDA Restricts Sale, Approves New Labeling Of Breast Implants
The FDA is restricting the sale and distribution of breast implants over concerns about the risks of the devices, limiting the products to healthcare providers and... 
Via Benzinga
Exposures Product Safety
What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report
In a word: Humira. 
Via The Motley Fool
Earnings Scheduled For October 29, 2021
Companies Reporting Before The Bell • Sify Technologies (NASDAQ:SIFY) is expected to report quarterly earnings at $0.02 per share on revenue of $97.70 million. •... 
Via Benzinga
Should Investors Worry About AbbVie?
AbbVie is about to lose its patent on the world's top-selling drug, but it may not be as bad as it sounds. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Price Over Earnings Overview: AbbVie
In the current market session, AbbVie Inc. (NYSE:ABBV) is trading at $109.16, after a 0.30% decrease. However, over the past month, the stock increased by 0.29%, and in the... 
Via Benzinga
AbbVie Takes Another Step Toward Its Post-Humira Future
Skyrizi is an important drug for AbbVie's future that could soon be approved for another indication in the E.U. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Will Chart Analysts Notice Bad Omen on AbbVie's Chart
If history is any guide, there may be trouble ahead for shares of AbbVie(NYSE:ABBV). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
What Could These Clinical Results Mean for AbbVie's Shareholders?
The results from phase 3 clinical trials suggest that Rinvoq could be an effective treatment for patients. 
Via The Motley Fool
How To Lower Risk On Your Biotech Plays
You can hit some big home runs in the biotech sector, but you need to manage your risk when trading these stocks. If you handle your risk properly, you’ll be able to take more big swings. 
Via Talk Markets
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
AbbVie: A Healthy Idea For Retirement Portfolios
The healthcare industry is among the cheapest sectors in today's market, and this pandemic has validated its importance for the economy and our overall well-being. Over the next decade, we will see... 
Via Talk Markets
Topics Economy Retirement
Exposures Economy Pension
A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO
Key takeaways Four rounds of fundraising together with IPO proceeds have given the Abbisko a cumulative war chest of almost $500 million Company is betting a significant portion... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
15 Dividend Stocks For The FIRE Type And Retired
Are you retired, or retired early? No doubt, in retirement, your needs are different than when you're working. In this article, discover 15 dividend stocks for retired people. 
Via Talk Markets
Topics Retirement
Exposures Pension
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ... 
Via Benzinga
Exposures Product Safety
7 Dividend Stocks To Buy for 2022 and Hold Forever
Buy these dividend stocks and forget them for 10 years, you will win big and should have little to worry about in the interim. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat
Johnson & Johnson (NYSE:JNJ) shares are higher Tuesday fo... 
Via Benzinga
3 Leading Healthcare Stocks to Buy in 2021 and Beyond
Three healthcare stocks that have momentum on their side and are good buys right now. 
Via The Motley Fool
3 Best Dividend Stocks for Retirement
These companies have positioned themselves to provide a generous and rising income stream. 
Via The Motley Fool
Want More Monthly Income? Invest in These 3 Stocks
They all pay more than double what you'll get with the average stock in the S&P 500. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based... 
Via Benzinga
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB... 
Via Talk Markets
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.